1、 CASAS DEZA D,BETORé GLARIA M E,SANZ PARíS A,et al.Mini nutritional assessment ‐ short form is a useful malnutrition screening tool in patients with liver cirrhosis,using the global leadership initiative for malnutrition criteria as the gold standard[J].Nut Clin Prac,2021,36(5):1003-1010. CASAS DEZA D,BETORé GLARIA M E,SANZ PARíS A,et al.Mini nutritional assessment ‐ short form is a useful malnutrition screening tool in patients with liver cirrhosis,using the global leadership initiative for malnutrition criteria as the gold standard[J].Nut Clin Prac,2021,36(5):1003-1010.
2、 PALMESE F,BOLONDI I,GIANNONE F A,et al.The analysis of food intake in patients with cirrhosis waiting for liver transplantation:A neglected step in the nutritional assessment[J].Nutrients,2019,11(10):2462. PALMESE F,BOLONDI I,GIANNONE F A,et al.The analysis of food intake in patients with cirrhosis waiting for liver transplantation:A neglected step in the nutritional assessment[J].Nutrients,2019,11(10):2462.
3、 吴梅,顾丽丽,杨艳,等.基于授权理论的干预模式在肝癌术后患者护理中的应用[J].临床与病理杂志,2023,43(5):1011-1018. 吴梅,顾丽丽,杨艳,等.基于授权理论的干预模式在肝癌术后患者护理中的应用[J].临床与病理杂志,2023,43(5):1011-1018.
4、 BISCHOFF S C,BERNAL W,DASARATHY S,et al.ESPEN practical guideline:Clinical nutrition in liver disease[J].Clin Nutr,2020,39(12):3533-3562. BISCHOFF S C,BERNAL W,DASARATHY S,et al.ESPEN practical guideline:Clinical nutrition in liver disease[J].Clin Nutr,2020,39(12):3533-3562.
5、 张晓轩,龙顺钦,杨小兵,等.健脾理气抑瘤方联合CIK治疗对晚期肝细胞癌患者免疫功能及生活质量的影响[J].广东医学,2016,37(3):441-444. 张晓轩,龙顺钦,杨小兵,等.健脾理气抑瘤方联合CIK治疗对晚期肝细胞癌患者免疫功能及生活质量的影响[J].广东医学,2016,37(3):441-444.
6、 唐明尧,黄微,陈媛,等.认知干预对接受射频治疗的肝细胞癌患者生活质量及负性情绪的影响[J].现代肿瘤医学,2020,28(23):4115-4119. 唐明尧,黄微,陈媛,等.认知干预对接受射频治疗的肝细胞癌患者生活质量及负性情绪的影响[J].现代肿瘤医学,2020,28(23):4115-4119.
7、 黄子寅,培尔顿·米吉提,凯比努尔·艾尔肯.EORTC QLQ-C30量表汇总评分在中国结直肠癌患者中的验证[J].中华肿瘤防治杂志,2022,29(16):1171-1176. 黄子寅,培尔顿·米吉提,凯比努尔·艾尔肯.EORTC QLQ-C30量表汇总评分在中国结直肠癌患者中的验证[J].中华肿瘤防治杂志,2022,29(16):1171-1176.
8、 XU L,WANG S,ZHUANG L,et al.Jian pi li qi decoction alleviated postembolization syndrome following transcatheter arterial chemoembolization for hepatocellular carcinoma:A randomized,double-blind,placebo-controlled trial[J].Integr Cancer Ther,2016,15(3):349-357. XU L,WANG S,ZHUANG L,et al.Jian pi li qi decoction alleviated postembolization syndrome following transcatheter arterial chemoembolization for hepatocellular carcinoma:A randomized,double-blind,placebo-controlled trial[J].Integr Cancer Ther,2016,15(3):349-357.
9、 CHEN R,YANG S,XU Z,et al.Validation and application of the Chinese version of the M.D.Anderson Symptom Inventory Gastrointestinal Cancer Module(MDASI-GI-C)[J].J Pain Symptom Manage,2019,57(4):820-827. CHEN R,YANG S,XU Z,et al.Validation and application of the Chinese version of the M.D.Anderson Symptom Inventory Gastrointestinal Cancer Module(MDASI-GI-C)[J].J Pain Symptom Manage,2019,57(4):820-827.
10、 VERMA M,KALMAN R,HORROW J,et al.Feasibility of a palliative care intervention within routine care of hepatocellular carcinoma:A pilot randomized controlled trial[J].J Palliat Med,2023,26(3):334-341. VERMA M,KALMAN R,HORROW J,et al.Feasibility of a palliative care intervention within routine care of hepatocellular carcinoma:A pilot randomized controlled trial[J].J Palliat Med,2023,26(3):334-341.
11、 European Association for the Study of the Liver.EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J].J Hepatol,2019,70(1):172-193. European Association for the Study of the Liver.EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J].J Hepatol,2019,70(1):172-193.
12、 李增宁,李晓玲,陈伟,等.肿瘤患者食欲评价和调节的专家共识[J].肿瘤代谢与营养电子杂志,2020,7(2):169-177. 李增宁,李晓玲,陈伟,等.肿瘤患者食欲评价和调节的专家共识[J].肿瘤代谢与营养电子杂志,2020,7(2):169-177.
13、 中国抗癌协会肿瘤营养专业委员会,全国卫生产业企业管理协会医学营养产业分会,浙江省医学会肿瘤营养与治疗学分会.肿瘤患者食欲下降的营养诊疗专家共识[J].肿瘤代谢与营养电子杂志,2022,9(3):312-319. 中国抗癌协会肿瘤营养专业委员会,全国卫生产业企业管理协会医学营养产业分会,浙江省医学会肿瘤营养与治疗学分会.肿瘤患者食欲下降的营养诊疗专家共识[J].肿瘤代谢与营养电子杂志,2022,9(3):312-319.
14、 ZHU Y,BLUNDELL J E,HOLSCHUH N M,et al.Validation of a mobile app-based visual analog scale for appetite measurement in the real world:A randomized digital clinical trial[J].Nutrients,2023,15(2):304. ZHU Y,BLUNDELL J E,HOLSCHUH N M,et al.Validation of a mobile app-based visual analog scale for appetite measurement in the real world:A randomized digital clinical trial[J].Nutrients,2023,15(2):304.
15、 段彤. 皮内针疗法治疗癌性厌食症的临床疗效观察[D].长沙:湖南中医药大学,2023. 段彤. 皮内针疗法治疗癌性厌食症的临床疗效观察[D].长沙:湖南中医药大学,2023.
16、 刘石红. 健脾益气法治疗癌症术后食欲不振临床观察[J].光明中医,2023,38(17):3360-3362. 刘石红. 健脾益气法治疗癌症术后食欲不振临床观察[J].光明中医,2023,38(17):3360-3362.
17、 吴叶琪,王睿.耳穴治疗肿瘤相关食欲减退的临床运用规律研究进展[J].中国中医药科技,2022,29(6):1132-1135. 吴叶琪,王睿.耳穴治疗肿瘤相关食欲减退的临床运用规律研究进展[J].中国中医药科技,2022,29(6):1132-1135.
18、 彭莉,王若宇,陈舒婷,等.吴茱萸穴位贴敷改善肝癌不同介入治疗所致胃肠道反应的护理研究[J].中医药导报,2023,29(4):98-103. 彭莉,王若宇,陈舒婷,等.吴茱萸穴位贴敷改善肝癌不同介入治疗所致胃肠道反应的护理研究[J].中医药导报,2023,29(4):98-103.
19、 靳飘洋,薛敬东,李婕.中医联合介入治疗原发性肝癌的研究进展[J].中西医结合肝病杂志,2023,33(9):857-860. 靳飘洋,薛敬东,李婕.中医联合介入治疗原发性肝癌的研究进展[J].中西医结合肝病杂志,2023,33(9):857-860.
20、 李杰,常金圆,陈佳阳,等.基于“运中调衡”法辨治肿瘤患者食欲减退[J].国际中医中药杂志,2023,45(6):780-783. 李杰,常金圆,陈佳阳,等.基于“运中调衡”法辨治肿瘤患者食欲减退[J].国际中医中药杂志,2023,45(6):780-783.
21、 杨如卉. 肝癌切除术后患者症状自我管理体验、自我管理现状及影响因素分析[D].新乡:新乡医学院,2022. 杨如卉. 肝癌切除术后患者症状自我管理体验、自我管理现状及影响因素分析[D].新乡:新乡医学院,2022.
22、 WAGNER M,PROBST P,HASELBECK-K?BLER M,et al.The problem of appetite loss after major abdominal surgery:A systematic review[J].Ann Surg,2022,276(2):256-269. WAGNER M,PROBST P,HASELBECK-K?BLER M,et al.The problem of appetite loss after major abdominal surgery:A systematic review[J].Ann Surg,2022,276(2):256-269.
23、 王琪,吕利明,薄纯圆,等.肿瘤患者癌性厌食评估与干预的最佳证据总结[J].护理学杂志,2023,38(23):25-29. 王琪,吕利明,薄纯圆,等.肿瘤患者癌性厌食评估与干预的最佳证据总结[J].护理学杂志,2023,38(23):25-29.
24、 胡雁. 症状科学的发展及研究趋势[J].护士进修杂志,2023,38(24):2209-2213. 胡雁. 症状科学的发展及研究趋势[J].护士进修杂志,2023,38(24):2209-2213.
25、 胡豆. 基于患者报告结局的肝癌患者围术期症状群与生活质量相关性的纵向研究[D].成都:电子科技大学,2023. 胡豆. 基于患者报告结局的肝癌患者围术期症状群与生活质量相关性的纵向研究[D].成都:电子科技大学,2023.
26、 ISHIZU Y,ISHIGAMI M,HONDA T,et al.Decreased appetite is associated with the presence of sarcopenia in patients with cirrhosis[J].Nutrition,2022(103-104):111807. ISHIZU Y,ISHIGAMI M,HONDA T,et al.Decreased appetite is associated with the presence of sarcopenia in patients with cirrhosis[J].Nutrition,2022(103-104):111807.
27、 TIAN T,GUO J,HU J L,et al.Advanced hepatocellular carcinoma and palliative care:A scoping review[J].BMJ Support Palliat Care,2024,14(2):163-170. TIAN T,GUO J,HU J L,et al.Advanced hepatocellular carcinoma and palliative care:A scoping review[J].BMJ Support Palliat Care,2024,14(2):163-170.
28、 LUO J,GAO B,LIN Z,et al.Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma:A meta-analysis[J].Front Oncol,2022(12):1010726. LUO J,GAO B,LIN Z,et al.Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma:A meta-analysis[J].Front Oncol,2022(12):1010726.
29、 BAAZIM H,ANTONIO-HERRERA L,BERGTHALER A.The interplay of immunology and cachexia in infection and cancer[J].Nat Rev Immunol,2022,22(5):309-321. BAAZIM H,ANTONIO-HERRERA L,BERGTHALER A.The interplay of immunology and cachexia in infection and cancer[J].Nat Rev Immunol,2022,22(5):309-321.
30、 RICH N E,PHEN S,DESAI N,et al.Cachexia is Prevalent in patients with hepatocellular carcinoma and associated with worse prognosis[J].Clin Gastroenterol Hepatol,2022,20(5):e1157-e1169. RICH N E,PHEN S,DESAI N,et al.Cachexia is Prevalent in patients with hepatocellular carcinoma and associated with worse prognosis[J].Clin Gastroenterol Hepatol,2022,20(5):e1157-e1169.
31、 KIM Y,KIM S R,KIM K,et al.Demographic,clinical and psychological predictors of malnutrition among people with liver cancer[J].Eur J Oncol Nurs,2023(68):102497. KIM Y,KIM S R,KIM K,et al.Demographic,clinical and psychological predictors of malnutrition among people with liver cancer[J].Eur J Oncol Nurs,2023(68):102497.
32、 王瑛,袁鹤立,赵利,等.伴营养不良风险的原发性肝癌患者临床特征及预后因素分析[J].中西医结合肝病杂志,2022,32(6):494-498. 王瑛,袁鹤立,赵利,等.伴营养不良风险的原发性肝癌患者临床特征及预后因素分析[J].中西医结合肝病杂志,2022,32(6):494-498.
33、 孟杨,侯婧悦,李洁,等.动态营养支持对原发性肝癌术后免疫功能及炎症应激反应的影响[J].现代消化及介入诊疗,2022,27(12):1578-1582. 孟杨,侯婧悦,李洁,等.动态营养支持对原发性肝癌术后免疫功能及炎症应激反应的影响[J].现代消化及介入诊疗,2022,27(12):1578-1582.
34、 XIE H,TIAN S,CUI L,et al.Adjuvant trans-arterial chemoembolization after hepatectomy significantly improves the prognosis of low-risk patients with R0-stage hepatocellular carcinoma[J]. Cancer Manag Res,2019(11):4065-4073. XIE H,TIAN S,CUI L,et al.Adjuvant trans-arterial chemoembolization after hepatectomy significantly improves the prognosis of low-risk patients with R0-stage hepatocellular carcinoma[J]. Cancer Manag Res,2019(11):4065-4073.
35、 陈墅圳,蒋文燕,刘杰.基于倾向性评分匹配分析系统免疫炎症指数对早、中期肝细胞癌术后早期复发的预测价值[J].广州医药,2023,54(10):83-89. 陈墅圳,蒋文燕,刘杰.基于倾向性评分匹配分析系统免疫炎症指数对早、中期肝细胞癌术后早期复发的预测价值[J].广州医药,2023,54(10):83-89.
36、 宋春花,王昆华,郭增清,等.中国常见恶性肿瘤患者营养状况调查[J].中国科学:生命科学,2020,50(12):1437-1452. 宋春花,王昆华,郭增清,等.中国常见恶性肿瘤患者营养状况调查[J].中国科学:生命科学,2020,50(12):1437-1452.
37、 方亮,熊晓云,方路,等.基于ESPEN标准探讨四种营养筛查工具对肝细胞肝癌患者的营养评估及预后价值[J].实用医学杂志,2020,36(20):2792-2796,2801. 方亮,熊晓云,方路,等.基于ESPEN标准探讨四种营养筛查工具对肝细胞肝癌患者的营养评估及预后价值[J].实用医学杂志,2020,36(20):2792-2796,2801.
38、 Sung H,Ferlay J,Siegel R L,et al.Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249. Sung H,Ferlay J,Siegel R L,et al.Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
39、 ZELLI V,COMPAGNONI C,CAPELLI R,et al.Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms:Focus on hepatocellular carcinoma[J].Front Oncol,2022(12):940056. ZELLI V,COMPAGNONI C,CAPELLI R,et al.Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms:Focus on hepatocellular carcinoma[J].Front Oncol,2022(12):940056.
40、 DEVARBHAVI H,ASRANI S K,ARAB J P,et al.Global burden of liver disease:2023 update[J].J Hepatol,2023,79(2):516-537. DEVARBHAVI H,ASRANI S K,ARAB J P,et al.Global burden of liver disease:2023 update[J].J Hepatol,2023,79(2):516-537.
41、 UKOVIC B,PORTER J.Nutrition interventions to improve the appetite of adults undergoing cancer treatment:A systematic review[J].Support Care Cancer,2020,28(10):4575-4583. UKOVIC B,PORTER J.Nutrition interventions to improve the appetite of adults undergoing cancer treatment:A systematic review[J].Support Care Cancer,2020,28(10):4575-4583.
42、 KAPLAN A,ROSENBLATT R.Symptom management in patients with cirrhosis:A practical guide[J].Curr Treat Options Gastroenterol,2022,20(2):144-159. KAPLAN A,ROSENBLATT R.Symptom management in patients with cirrhosis:A practical guide[J].Curr Treat Options Gastroenterol,2022,20(2):144-159.
43、 MUSCARITOLI M,ARENDS J,BACHMANN P,et al.ESPEN practical guideline:Clinical nutrition in cancer[J].Clin Nutr,2021,40(5):2898-2913. MUSCARITOLI M,ARENDS J,BACHMANN P,et al.ESPEN practical guideline:Clinical nutrition in cancer[J].Clin Nutr,2021,40(5):2898-2913.
44、 HARIYANTO T I,KURNIAWAN A.Appetite problem in cancer patients:Pathophysiology,diagnosis,and treatment[J].Cancer Treat Res Commun,2021(27):100336. HARIYANTO T I,KURNIAWAN A.Appetite problem in cancer patients:Pathophysiology,diagnosis,and treatment[J].Cancer Treat Res Commun,2021(27):100336.
45、 MOORE H,WHITE M J,FINLAYSON G,et al.Can smartphone-based response inhibition training elicit sustained changes in appetite,preference,and cravings for energy-dense foods?A free-living randomized controlled trial[J].Br J Health Psychol,2024,29(1):165-184. MOORE H,WHITE M J,FINLAYSON G,et al.Can smartphone-based response inhibition training elicit sustained changes in appetite,preference,and cravings for energy-dense foods?A free-living randomized controlled trial[J].Br J Health Psychol,2024,29(1):165-184.
